Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and ...

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% ...

With a market cap of $122.6 billion, Vertex Pharmaceuticals Incorporated (VRTX) operates as a global biotechnology company ...

When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects.

The non-profit Institute for Clinical and Economic Review has issued a lukewarm final evidence report on Vertex Pharmaceuticals' (NASDAQ:VRTX) non-opioid pain medicine Journavx (suzetrigine).

Equity markets have been seesawing for the past two weeks. Stocks fell hard after President Donald Trump announced his tariff ...

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma Kewalramani, M.D., to $21.5 million, ...

Fye highlighted that Vertex’s 2025 revenue guide of $11.75 ... A quicker-than-expected ramp-up for Journavx Faster patient dosing for gene-editing therapy Casgevy. The former is shaping up ...

The biopharmaceutical industry is positioned for continued recovery, driven by recent FDA approvals and billion-dollar ...

The recent selloff has GreensKeeper excited about the price declines. Click here to read on to learn about our response to ...

Vertex is appealing simply by virtue of its ... as the apparent robust demand for Journavx indicates. I think this stock is well worth a look as a somewhat offbeat way to play the biotech and ...